Cilostazol effective drug in preventing stroke in men than women
Dual antiplatelet therapy (DAPT) is highly effective in preventing atherothrombotic complications in patients with previous myocardial infarction and current guidelines recommend the prescription of DAPT for at least 12 months in all patients experiencing an acute event. now, Long-term dual antiplatelet therapy (DAPT) using cilostazol significantly reduces recurrent ischemic stroke in men, but not in women as reported in the studywhich was presented at the International Stroke Conference.
The results were drawn based on about 2000 patients in the Cilostazol Stroke Prevention Study Combination who received dual antiplatelet therapy using cilostazol, compared with men who received monotherapy. In contrast, the rate of recurrent stroke was not significantly different between women who received dual antiplatelet therapy using cilostazol and those who received monotherapy.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.